1374p 30.0 2.2%
Last Trade - 06/12/19
| Market Cap | £2.83bn |
| Enterprise Value | £2.74bn |
| Revenue | £259.9m |
| Position in Universe | 241st / 1840 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | TTM | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2019
|
31st Dec 2020
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways. The Company is engaged in data sharing and ecommerce in the life sciences. The Company focuses on helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use its affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. It has approximately 10 locations located in the world, through life science research hubs, enabling local services and multi-language support.
| Last Annual | June 30th, 2019 |
| Last Interim | June 30th, 2019 |
| Incorporated | February 12, 1998 |
| Public Since | November 3, 2005 |
| No. of Shareholders: | n/a |
| No. of Employees: | 1,155 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 , , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 206,015,013 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Clifford Allbutt Building,Cambridge Biomedical Campus Hills Road, CAMBRIDGE, CB2 0AH, United Kingdom |
| Web | http://www.abcam.com/ |
| Phone | +44 1223 696000 |
| Contact | James Staveley (Vice President - Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
